Current treatment of superficial mycosis;Tratamiento actual de las micosis superficiales

Revista Iberoamericana de Micologia

Volumn 16, Issue SUPPL. 1, 1999, Pages

  Carazo, José Luis Sánchez ^a   Losada, Luisa Obón ^a   Sanjuan, Virginia Pont ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

Antigungal drugs; Fluconazole; Griseofulvin; Itraconazole; Terbinafine; Triazole

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; RIFAMPICIN; SULFONYLUREA DERIVATIVE; TERBINAFINE; TRIAZOLE DERIVATIVE; WARFARIN;

ADVERSE DRUG REACTION; CONFERENCE PAPER; DERMATOMYCOSIS; DRUG ABSORPTION; GASTROINTESTINAL TOXICITY; HUMAN; NONHUMAN; PHARMACOKINETICS;

EID: 0348232345     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Medoff G, Kobayashi GA. The polyenes. In. Speller DCE. ed Antifungal chemotherapy. Chichester, John Wiley & sons, 1980:3-33
2. Woolley DW Some biological effects produced by benzimidazole and their reversal by purines J Biol Chem 1944;152:225-232.
3. Gentles JC. Experimental ringworm in guinea pigs oral treatment with griseofulvin. Nature 1958;182 476-477.
4. Documento de consenso en micosis superficiales. M. Lecha, V. Delgado (Coordinadores) Madrid, Grupo Aula Médica, 1999.
5. Dhanaraju MD, Kumaran KS, Baskaran T Moorthy MS Enhancement of bioavailability of griseofulvin by its complexation with beta-cyclodextrin Drug Dev Ind Pharm 1998; 24 583-587
6. Aste N, Pau M, Biggio P. Tinea capitis in children in the district of Cagliari, Italy. Mycoses 1997;40: 231-233.
7. Mock M, Monod M, Baudraz-Rosselet F, Panizzon RG. Tinea capitis dermatophytes: susceptibility to antifungal drugs tested in vitro and in vivo. Dermatology 1998;197:361-7
8. Rademaker M, Havill S Griseofulvin and terbinafine in the treatment of tinea capitis in children. N Z Med J 1998;111 55-57
9. Vanden Bossche H, Lauwers W, Willemsens G, Marichal P, Cornelissen F, Cools W. Molecular basis for the antimycotic and antibacterial activity of N-susbstituted imidazoles and triazoles: the inhibition of isoprenoid biosynthesis. Pestic Sci 1984; 15 188-198
10. Nolting SK, Sánchez Carazo J, De Boulle K. et al. Oral treatment schedules for onychomycosis a study of patient preference. Int J Dermatol 1998; 37 454-456.
11. Loftsson T, Hjaltalin Olafsson J. Cyclodextrins new drug delivery systems in dermatology Int J Dermatol 1998, 37:241-246.
12. Reynes J, Bazin C, Ajana F, et al Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus infected adults with oral candidiasis. Antimicrob Agents Chemother 1997; 41: 2554-2558.
13. Gupta AK, Solomon RS, Adam P Itraconazole oral solution for the treatment of tinea capitis. Br J Dermatol 1998;139:104-106
14. Brammer KW, Farrow PR,Faulkner JK Pharmacokinetics and tissue penetration of fluconazole in humans Rev Infect Dis 1990;12 (Suppl): S138-S126
15. Montero-Gei F, Perera A. Therapy with fluconazole for tinea corporis, tinea cruris and tinea pedis Clin Infect Dis 1992; 14 (Suppl): S77-S81
16. Drake L, Babel D, Stewart DM. Once weekly fluconazole (150, 300 or 450 mg) in the treatment of distal subungueal onychomycosis of the fingernail J Am Acad Dermatol 1998; 38: S87-S94.
17. Marco F, Pfaller NMA , Messer S. Jones N In vitro activities of voriconazole (UK-109,496) and four otherantifungal agents against 394 clinicalilsolates of Candida spp Antimicrob Agents Chemother 1998; 42:161-163.
18. Gupta AK, Sauder DN, Shear NH. Antifungal agents An overview. Part I. J Am Acad Dermatol 1994;30 677-698.
19. Bada Ainsa JL Tratamiento farmacológico de las Micosis. En Torres Rodriguez JM (Ed). Micosis que afectan a la piel y mucosas Barcelona, Doyma, 1989 137-163.
20. Font E Freixes J, Juive J. Perfil de un nuevo antimicótico tópico. Eberconazol. Rev Iberoam Micol 1995; 12:16-17
21. Petranyi G, Ryder NS, Stuetz A. Allyllamine derivates: new class of synthetic antifungal agents inhibiting fungal squalene epoxidase Science 1984; 224:1239-1241
22. Ryder NS, Stuetz A, Nussbaumer P. Squalene epoxidase inhibitors' structural determinants for activity and selectivity of allylamines and related compounds. In Nes WD, Parish EJ. Trzaskos JM (Eds.) Regulation of isopentenoid metabolism. Washington DC, American Chemical Society,1992:192-204.
23. Goodfield MJD, Andrew L, Evans EGV. Short term treatment of dermatophyte onychomycosis with terbinafine. Br J Dermatol 1992;126 (Suppl 39):33-35.
24. Del Palacio A, Cuétara S, Gonzalez Ruiz A Valle A. Reservas sobre la utilizacion de terbinafina (Lamisil) en tiñas del cuero cabelludo por Microsporum canis Actas Dermosifiliograf 1998;89:317-318.
25. Krafchik B The clinical efficacy of terbinafine in the treatment of tinea capitis. Rev Contemp Pharmacother 1997;8:313-324.
26. Haria M, Bryson HM. Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other fungal infection Drugs 1995; 49: 103-120.
27. Marty JP. Amorolfine nail lacquer a galenical innovation. Third Congress of the European Academy of Dermatology, Copenhagen, 1993:180
28. Kramer K, Paul E. Contact dermatitis from amorolfine containing cream and nail lacquer. Contact Dermatitis 1996;34:145.
29. Ulbricht H, Worz K Therapy with ciclopirox lacquer of onychomycoses caused by molds. Mycoses 1994; 37 (Suppl 1) 97-100